FDA greenlights expansion of BiVacor artificial heart study
December 18, 2024
BiVacor announced today that it completed the first phase of an FDA early feasibility study (EFS) for its Total Artificial Heart (TAH).
BiVacor announced today that it completed the first phase of an FDA early feasibility study (EFS) for its Total Artificial Heart (TAH).
Researchers from UC Irvine’s Departments of Radiological Sciences and Biomedical Engineering recently published a study in the journal Science Advances in which they introduce a technology that achieves 3D imaging with a single X-ray projection called X-ray–Induced Acoustic Computed Tomography (XACT).